VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event …
Uncategorized
Physicians maintain agency in AI decision-making
SAN DIEGO — Physicians should maintain agency in shaping the future of AI to augment their clinical workflow and medical decision-making processes, according to a presenter at AIMed25.“It is important to make sure we have a clinical voice in all aspect…
Uncategorized
ABAIM educates, certifies health care professionals
SAN DIEGO — The American Board of AI in Medicine educates health care professionals about the role of AI in medicine and provides a pathway to board-level certification, according to a presenter at AIMed25.“These are live courses, which is much better …
Uncategorized
Inherited retinal diseases require comprehensive approach
NEW YORK — Effective management of inherited retinal diseases requires a comprehensive approach to diagnosis and treatment, according to a speaker at OSN New York Retina.In a presentation, Mark P. Breazzano, MD, FACS, of Flaum Eye Institute at the Univ…
Uncategorized
FDA appoints cancer leader Pazdur to head drug center
The FDA on Nov. 11 appointed Richard Pazdur, MD, as the new director of the Center for Drug Evaluation and Research.Pazdur joined the FDA in 1999 and recently served as founding director of the Oncology Center of Excellence.“I’m honored to lead the CDE…
Uncategorized
VIDEO: UBX1325 may have utility as adjunctive agent in diabetic macular edema
ORLANDO — In this video from the American Academy of Ophthalmology meeting, David A. Eichenbaum, MD, FASRS, discusses phase 2b ASPIRE study results comparing UBX1325 vs. aflibercept in patients with diabetic macular edema.In the phase 2b study, researc…